Turning Point Therapeutics Inc

NASDAQ:TPTX   3:59:16 PM EDT
70.57
+1.22 (+1.76%)
Products

Turning Point Says Granted FDA Breakthrough Therapy Designation For Repotrectinib Treatment

Published: 12/08/2020 14:01 GMT
Turning Point Therapeutics Inc (TPTX) - Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With Ros1-positive Metastatic Non-small Cell Lung Cancer Who Have Not Been Treated With a Ros1 Tyrosine Kinase Inhibitor.